Tazemetostat in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Propensity Score-Matched Analysis of E7438-G000-101 Trial Outcomes Tazemetostat, an oral enhancer of zeste homolog 2 (EZH2) inhibitor, received FDA approval based on a phase 2 study (NCT01897571); in this study, the ...